Form: 4

Statement of changes in beneficial ownership of securities

January 24, 2024

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kumar Dinesh M.
(Last) (First) (Middle)
1668 S. GARFIELD AVE
2ND FLOOR
(Street)
ALHAMBRA CA 91801
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Apollo Medical Holdings, Inc. [ AMEH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See remarks
3. Date of Earliest Transaction (Month/Day/Year)
01/23/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/23/2024 A 85,130(1) A $0 85,130 D
Common Stock 01/23/2024 A 16,316(2) A $0 101,446 D
Common Stock 01/23/2024 A 16,316(3) A $0 117,762 D
Common Stock 01/23/2024 A 13,053(4) A $0 130,815 D
Common Stock 01/23/2024 A 13,053(5) A $0 143,868 D
Common Stock 01/23/2024 A 6,527(6) A $0 150,395(7)(8) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's Employment Inducement Award Plan. Provided the Reporting Person is still employed with the Issuer on the date of vesting, the shares will vest in three equal annual installments beginning on January 23, 2025, subject to accelerated vesting in certain cases.
2. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's Employment Inducement Award Plan. Provided the Reporting Person is still employed with the Issuer on the date of vesting, and subject to the achievement of applicable pre-established performance goals, half of the shares will vest in four equal semi-annual installments beginning on July 1, 2024 and half of the shares will vest in four equal semi-annual installments beginning on July 1, 2024.
3. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's Employment Inducement Award Plan. Provided the Reporting Person is still employed with the Issuer on the date of vesting, and subject to the achievement of applicable performance goals, half of the shares will vest in four equal semi-annual installments beginning on July 1, 2024 and half of the shares will vest in four equal semi-annual installments beginning on July 1, 2024.
4. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's Employment Inducement Award Plan. Provided the Reporting Person is still employed with the Issuer on the date of vesting, and subject to the achievement of applicable pre-established performance goals, half of the shares will vest in four equal semi-annual installments beginning on July 1, 2024 and half of the shares will vest in four equal semi-annual installments beginning on July 1, 2024.
5. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's Employment Inducement Award Plan. Provided the Reporting Person is still employed with the Issuer on the date of vesting, and subject to the achievement of applicable pre-established performance goals, the shares will vest in four equal semi-annual installments beginning on July 1, 2024.
6. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's Employment Inducement Award Plan. Provided the Reporting Person is still employed with the Issuer on the date of vesting, and subject to the achievement of applicable pre-established performance goals, half of the shares will vest in four equal semi-annual installments beginning on July 1, 2024 and half of the shares will vest in four equal semi-annual installments beginning on July 1, 2024.
7. Includes 150,395 shares of restricted stock, which will vest as follows (in each case subject to continuous employment with the Issuer): (i) 85,130 shares, which will vest in three equal annual installments beginning on January 23, 2025; (ii) 16,316 shares, half of which will vest in four equal semi-annual installments beginning July 1, 2024 and half of which will vest in four equal semi-annual installments beginning July 1, 2024, in each case subject to the achievement of certain performance goals; (iii) 16,316 shares, half of which will vest in four equal semi-annual installments beginning July 1, 2024 and half of which will vest in four equal semi-annual installments beginning July 1, 2024, in each case subject to the achievement of certain performance goals;
8. (cont.) (iv) 13,053 shares, half of which will vest in four equal semi-annual installments beginning July 1, 2024 and half of which will vest in four equal semi-annual installments beginning July 1, 2024, in each case subject to the achievement of certain performance goals; (v) 13,053 shares, which will vest in four equal semi-annual installments beginning July 1, 2024, subject to the achievement of certain performance goals; and (vi) 6,527 shares, half of which will vest in four equal semi-annual installments beginning July 1, 2024 and half of which will vest in four equal semi-annual installments beginning July 1, 2024, in each case subject to the achievement of certain performance goals.
Remarks:
Chief Medical Officer of ApolloCare Enablement of Nevada, Inc., a wholly owned subsidiary of Apollo Medical Holdings, Inc.
/s/ Dinesh M. Kumar 01/24/2024
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.